Latvia’s Oncology Crisis: Funding Gaps Threaten Patient Care and Infrastructure

Latvia is currently grappling with a critical shortfall in oncology funding that spans both patient medication and essential hospital infrastructure. While the country’s cancer care metrics generally outperform those of its Eastern European neighbors, a growing gap in state funding is forcing thousands of patients to rely on charities for life-saving treatment and leaving major medical facilities in a state of reconstruction limbo.

The Battle for Vital Oncology Medications

President Edgars Rinkevics is stepping in to address a systemic failure in the reimbursement of oncology medicines. The urgency follows an open letter from the support group Palidzesim Viens Otram (Help Each Other), which advocates for an additional EUR 150 million from the state budget.

The support group argues that this funding is necessary to include 80 vital medications on the list of reimbursable medicines. The current system has left approximately 7,000 patients waiting for these treatments. Many of these innovative medicines cost thousands of euros, making them unaffordable for the average Latvian family.

The Failure of the Reimbursement Cap

Currently, the National Health Service sets a maximum compensation limit of EUR 30,000 per year. Yet, this cap is often insufficient for the cost of innovative therapies. The burden of funding life-saving care has shifted from the state to society.

• Charity Dependence: In the first three months of this year alone, over 47 oncology patients turned to charities after being refused individual reimbursement by the National Health Service.
• Funding Gap: More than EUR 2 million is required to provide help to all patients who have been denied state support for non-reimbursable medicines.

Stalled Infrastructure: The Latvian Oncology Centre

Beyond medication, the physical infrastructure for cancer care is in jeopardy. Funding for the reconstruction of the Latvian Oncology Centre (LOC) at Riga East Clinical University Hospital (RAKUS) remains stalled. Armands Sīviņš, head of the LOC Oncosurgery Clinic, has warned that the lack of resources is directly affecting the accessibility of care, particularly as the demand for chemotherapy treatments rises.

The Ministry of Health (MoH) has yet to allocate a specific funding source for the reconstruction. According to reports, the MoH proposed reallocating 68.3 million euros from the sixth round of the European Regional Development Fund (ERDF) to other projects, such as the A2 building project at Pauls Stradiņš Clinical University Hospital (PSKUS) and the Infectious Diseases and Pulmonary Health Centre (LIC) at RAKUS.

State Budget vs. European Funds

Prime Minister Evika Silinja has stated that there are no funds available in the state budget for the LOC reconstruction. Instead, the government intends to seek financing through European funds. Silinja attributed the financial difficulties to delays in construction work that necessitated resolving financial issues across multiple medical institutions simultaneously.

Budgetary Priorities and Public Debate

The lack of state funding for oncology has sparked a heated public debate regarding Latvia’s national priorities. While the government claims a lack of budget for the cancer center, Latvia continues to provide significant military aid to Ukraine, including participation in an international coalition for drone supplies and joint arms procurement funds.

This contrast has led citizens and experts to question why vital medical projects must seek external funding while military spending remains stable.

Regional Performance Context

Despite these domestic funding struggles, Latvia remains competitive on a regional scale. A study published in The Lancet Oncology indicates that the three high-income Baltic countries perform better than countries in Eastern and Central Europe across several metrics, including radiotherapy capacity, the availability of radiation oncologists, and cancer mortality-to-incidence ratios.

Key Takeaways

• Medication Gap: Support groups are calling for EUR 150 million to cover 80 vital oncology drugs for 7,000 patients.
• Infrastructure Delay: The reconstruction of the Latvian Oncology Centre is stalled due to a lack of dedicated state funding.
• Funding Strategy: The government is pivoting toward European funds for hospital reconstruction rather than the state budget.
• Social Impact: Patients are increasingly forced to rely on charities for innovative medicines that exceed the EUR 30,000 annual reimbursement cap.